185 related articles for article (PubMed ID: 20716241)
1. Impaired irinotecan biotransformation in hepatic microsomal fractions from patients with chronic liver disease.
d'Esposito F; Nebot N; Edwards RJ; Murray M
Br J Clin Pharmacol; 2010 Sep; 70(3):400-8. PubMed ID: 20716241
[TBL] [Abstract][Full Text] [Related]
2. A new metabolite of irinotecan in which formation is mediated by human hepatic cytochrome P-450 3A4.
Sai K; Kaniwa N; Ozawa S; Sawada JI
Drug Metab Dispos; 2001 Nov; 29(11):1505-13. PubMed ID: 11602529
[TBL] [Abstract][Full Text] [Related]
3. Biosynthesis of an aminopiperidino metabolite of irinotecan [7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecine] by human hepatic microsomes.
Haaz MC; Riché C; Rivory LP; Robert J
Drug Metab Dispos; 1998 Aug; 26(8):769-74. PubMed ID: 9698291
[TBL] [Abstract][Full Text] [Related]
4. Modulation of irinotecan metabolism by ketoconazole.
Kehrer DF; Mathijssen RH; Verweij J; de Bruijn P; Sparreboom A
J Clin Oncol; 2002 Jul; 20(14):3122-9. PubMed ID: 12118026
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.
Santos A; Zanetta S; Cresteil T; Deroussent A; Pein F; Raymond E; Vernillet L; Risse ML; Boige V; Gouyette A; Vassal G
Clin Cancer Res; 2000 May; 6(5):2012-20. PubMed ID: 10815927
[TBL] [Abstract][Full Text] [Related]
6. Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3.
Sanghani SP; Quinney SK; Fredenburg TB; Davis WI; Murry DJ; Bosron WF
Drug Metab Dispos; 2004 May; 32(5):505-11. PubMed ID: 15100172
[TBL] [Abstract][Full Text] [Related]
7. Determination of drug interactions occurring with the metabolic pathways of irinotecan.
Charasson V; Haaz MC; Robert J
Drug Metab Dispos; 2002 Jun; 30(6):731-3. PubMed ID: 12019202
[TBL] [Abstract][Full Text] [Related]
8. Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms.
Yokokawa A; Kaneko S; Endo S; Minowa Y; Ayukawa H; Hirano R; Nagashima F; Naruge D; Okano N; Kobayashi T; Kawai K; Furuse J; Furuta T; Shibasaki H
Eur J Drug Metab Pharmacokinet; 2021 Mar; 46(2):317-324. PubMed ID: 33619631
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions.
Haaz MC; Rivory L; Riché C; Vernillet L; Robert J
Cancer Res; 1998 Feb; 58(3):468-72. PubMed ID: 9458091
[TBL] [Abstract][Full Text] [Related]
10. Gefitinib (Iressa) inhibits the CYP3A4-mediated formation of 7-ethyl-10-(4-amino-1-piperidino)carbonyloxycamptothecin but activates that of 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]carbonyloxycamptothecin from irinotecan.
Fujita K; Ando Y; Narabayashi M; Miya T; Nagashima F; Yamamoto W; Kodama K; Araki K; Endo H; Sasaki Y
Drug Metab Dispos; 2005 Dec; 33(12):1785-90. PubMed ID: 16123050
[TBL] [Abstract][Full Text] [Related]
11. Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38.
Dodds HM; Haaz MC; Riou JF; Robert J; Rivory LP
J Pharmacol Exp Ther; 1998 Jul; 286(1):578-83. PubMed ID: 9655905
[TBL] [Abstract][Full Text] [Related]
12. Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan.
van Erp NP; Baker SD; Zhao M; Rudek MA; Guchelaar HJ; Nortier JW; Sparreboom A; Gelderblom H
Clin Cancer Res; 2005 Nov; 11(21):7800-6. PubMed ID: 16278402
[TBL] [Abstract][Full Text] [Related]
13. Conversion of the CPT-11 metabolite APC to SN-38 by rabbit liver carboxylesterase.
Guichard SM; Morton CL; Krull EJ; Stewart CF; Danks MK; Potter PM
Clin Cancer Res; 1998 Dec; 4(12):3089-94. PubMed ID: 9865925
[TBL] [Abstract][Full Text] [Related]
14. The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms.
Haaz MC; Rivory LP; Riché C; Robert J
Naunyn Schmiedebergs Arch Pharmacol; 1997 Aug; 356(2):257-62. PubMed ID: 9272733
[TBL] [Abstract][Full Text] [Related]
15. Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes.
Hanioka N; Ozawa S; Jinno H; Tanaka-Kagawa T; Nishimura T; Ando M; Sawada Ji J
Drug Metab Dispos; 2002 Apr; 30(4):391-6. PubMed ID: 11901092
[TBL] [Abstract][Full Text] [Related]
16. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients.
Rivory LP; Riou JF; Haaz MC; Sable S; Vuilhorgne M; Commerçon A; Pond SM; Robert J
Cancer Res; 1996 Aug; 56(16):3689-94. PubMed ID: 8706009
[TBL] [Abstract][Full Text] [Related]
17. Influence of phenytoin on the disposition of irinotecan: a case report.
Murry DJ; Cherrick I; Salama V; Berg S; Bernstein M; Kuttesch N; Blaney SM
J Pediatr Hematol Oncol; 2002 Feb; 24(2):130-3. PubMed ID: 11990699
[TBL] [Abstract][Full Text] [Related]
18. Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients.
Sai K; Saito Y; Tatewaki N; Hosokawa M; Kaniwa N; Nishimaki-Mogami T; Naito M; Sawada J; Shirao K; Hamaguchi T; Yamamoto N; Kunitoh H; Tamura T; Yamada Y; Ohe Y; Yoshida T; Minami H; Ohtsu A; Matsumura Y; Saijo N; Okuda H
Br J Clin Pharmacol; 2010 Aug; 70(2):222-33. PubMed ID: 20653675
[TBL] [Abstract][Full Text] [Related]
19. In vitro activation of irinotecan to SN-38 by human liver and intestine.
Ahmed F; Vyas V; Cornfield A; Goodin S; Ravikumar TS; Rubin EH; Gupta E
Anticancer Res; 1999; 19(3A):2067-71. PubMed ID: 10470149
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacokinetics of irinotecan.
Chabot GG
Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
